A nonlinear mixed effects pharmacokinetic model for dapagliflozin and dapagliflozin 3-O-glucuronide in renal or hepatic impairment

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 5, 2013, Pages

  Van Der Walt, J S ^a   Hong, Y ^b   Zhang, L ^b   Pfister, M ^b   Boulton, D W ^b   Karlsson, M O ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DAPAGLIFLOZIN; DAPAGLIFLOZIN 3 O GLUCURONIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG METABOLISM; DRUG SAFETY; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIVER DYSFUNCTION; PRIORITY JOURNAL; REVIEW; SIMULATION; SINGLE DRUG DOSE;

EID: 84881150066     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.20     Document Type: Review

References (25)

1. Wright, E.M. Renal Na(+)-glucose cotransporters. Am. J. Physiol. Renal Physiol. 280, F10-F18 (2001).
2. Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D. & Pfister, M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513-519 (2009).
3. 14C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. Br. J. Clin. Pharmacol. 75, 763-768 (2013).
4. Kasichayanula, S. et al. Disposition and mass balance of [14C]-dapagliflozin after single oral doses in healthy male volunteers. (American Association of Pharmaceutical Scientists, Atlanta, GA, 2008).
5. Molitch, M.E., DeFronzo, R.A., Franz, M.J., Keane, W.F., Mogensen, C.E. & Parving, H.H.; American Diabetes Association. Diabetic nephropathy. Diabetes Care 26 (suppl. 1), S94-S98 (2003).
6. Fraser, A., Harris, R., Sattar, N., Ebrahim, S., Davey Smith, G. & Lawlor, D.A. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 32, 741-750 (2009).
7. Kasichayanula, S. et al. Influence of renal function on dapagliflozin pharmacodynamics in patients with type 2 diabetes mellitus [abstr. TH-PO525]. In American Society of Nephrology (Philadelphia, PA, 2011).
8. Kasichayanula, S. et al. Influence of renal function on dapagliflozin pharmacokinetics in healthy subjects and in patients with type 2 diabetes mellitus [abstr. TH-PO526]. In American Society of Nephrology. (Philadelphia, PA, 2011).
9. Kasichayanula, S., Liu, X., Zhang, W., Pfister, M., LaCreta, F.P. & Boulton, D.W. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an openlabel, parallel-group, single-dose study. Clin. Ther. 33, 1798-1808 (2011).
10. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42, S1-201 (2003).
11. Kasichayanula, S. et al. The influence of kidney function on dapagliflozin exposure, metabolism, and efficacy in healthy subjects and in patients with type 2 diabetes mellitus. Br. J. Clin. Pharmacol. (2012); e-pub ahead of print (doi:10.1111/bcp.12056).
12. Betrosian, A.P., Agarwal, B. & Douzinas, E.E. Acute renal dysfunction in liver diseases. World J. Gastroenterol. 13, 5552-5559 (2007).
13. Nishimura, M. & Naito, S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. Drug Metab. Pharmacokinet. 21, 357-374 (2006).
14. Nolin, T.D. Altered nonrenal drug clearance in ESRD. Curr. Opin. Nephrol. Hypertens. 17, 555-559 (2008).
15. Durkalski, V. & Berger, V.W. Categorizing data. In Encyclopedia of Statistics in Behavioral Science (John Wiley & Sons, Ltd., 2005); published online 15 October 2005 (doi:10.1002/0470013192.bsa077).
16. H inderling, P.H. & Shi, J. Absolute bioavailability estimated from oral data. J. Pharm. Sci. 84, 385-386 (1995).
17. H inderling, P.H. Evaluation of a novel method to estimate absolute bioavailability of drugs from oral data. Biopharm. Drug Dispos. 24, 1-16 (2003).
18. H amrén, B., Ericsson, H., Samuelsson, O. & Karlsson, M.O. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function- evidence of interconversion. Br. J. Clin. Pharmacol. 65, 855-863 (2008).
19. H inderling, P.H. Biased estimates of nonrenal clearance. J. Pharm. Sci. 90, 960-966 (2001).
20. Kohan, D.E. et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment [abstr. TH-PO524]. In American Society of Nephrology (Philadelphia, PA, 2011).
21. Zhang, L., Feng, Y., List, J., Kasichayanula, S. & Pfister, M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes. Obes. Metab. 12, 510-516 (2010).
22. Karlsson, M.O., Beal, S.L. & Sheiner, L.B. Three new residual error models for population PK/PD analyses. J. Pharmacokinet. Biopharm. 23, 651-672 (1995).
23. Savic, R.M., Jonker, D.M., Kerbusch, T. & Karlsson, M.O. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34, 711-726 (2007).
24. Khandelwal, A., Harling, K., Jonsson, E.N., Hooker, A.C. & Karlsson, M.O. A fast method for testing covariates in population PK/PD Models. AAPS J. 13, 464-472 (2011).
25. Bergstrand, M., Hooker, A.C., Wallin, J.E. & Karlsson, M.O. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13, 143-151 (2011).